Connect with us

Company News

USFDA Completes Inspection of Biocon’s Telangana Plant, Finds no Fault

Biotechnology major Biocon said the US health regulator has completed the inspection of its Telangana manufacturing facility without making any observations. “The United States Food and Drug Administration (USFDA) conducted a good manufacturing practice (GMP) inspection of our active pharmaceutical ingredients (APIs) manufacturing facility at Telangana from December 12-14, 2018,” Biocon said in a regulatory filing. The inspection was concluded without any observations and no Form 483 was issued, the company added. A Form 483, is issued by the USFDA to notify a company’s management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection. – Business Standard

Copyright © 2024 Medical Buyer

error: Content is protected !!